[go: up one dir, main page]

WO2011008230A3 - Rapamycin derivatives and ethers of n-propanolamines and uses related to infection - Google Patents

Rapamycin derivatives and ethers of n-propanolamines and uses related to infection Download PDF

Info

Publication number
WO2011008230A3
WO2011008230A3 PCT/US2010/001279 US2010001279W WO2011008230A3 WO 2011008230 A3 WO2011008230 A3 WO 2011008230A3 US 2010001279 W US2010001279 W US 2010001279W WO 2011008230 A3 WO2011008230 A3 WO 2011008230A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
propanolamines
ethers
rapamycin derivatives
uses related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/001279
Other languages
French (fr)
Other versions
WO2011008230A2 (en
Inventor
Natalie Mcdonald
Thomas Hodge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zirus Inc
Original Assignee
Zirus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zirus Inc filed Critical Zirus Inc
Publication of WO2011008230A2 publication Critical patent/WO2011008230A2/en
Publication of WO2011008230A3 publication Critical patent/WO2011008230A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to the use of rapamycin derivatives and ethers of N- propanolamines for decreasing infection by a pathogen. More particularly, the invention relates to the use of O-alkylated rapamycin derivatives, as well as bepridil, for decreasing viral infection.
PCT/US2010/001279 2009-04-29 2010-04-29 Rapamycin derivatives and ethers of n-propanolamines and uses related to infection Ceased WO2011008230A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21484109P 2009-04-29 2009-04-29
US61/214,841 2009-04-29
US21508409P 2009-05-01 2009-05-01
US61/215,084 2009-05-01
US27136209P 2009-07-20 2009-07-20
US61/271,362 2009-07-20

Publications (2)

Publication Number Publication Date
WO2011008230A2 WO2011008230A2 (en) 2011-01-20
WO2011008230A3 true WO2011008230A3 (en) 2011-05-12

Family

ID=43450024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001279 Ceased WO2011008230A2 (en) 2009-04-29 2010-04-29 Rapamycin derivatives and ethers of n-propanolamines and uses related to infection

Country Status (1)

Country Link
WO (1) WO2011008230A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016098128A1 (en) 2014-12-16 2016-06-23 Council Of Scientific & Industrial Research Process for the preparation of bepridil
CN115998877A (en) * 2022-12-29 2023-04-25 深圳友道聚财科技企业(有限合伙) Application of CMPK2 inhibitor in preparation of medicine for preventing and treating respiratory syncytial virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIGITT DAU ET AL.: "The relationship between HIV infection and cardiovascular disease", CURRENT CARDIOLOGY REVIEWS, vol. 4, 2008, pages 203 - 218, XP009107943, DOI: doi:10.2174/157340308785160589 *
JOCELYN ROY ET AL.: "The immunosuppressant rapamycin repress human immunodeficiency virus type 1 replication", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, November 2002 (2002-11-01), pages 3477 - 3455 *
KRISHNA KADAVERU ET AL.: "Viral infection and human disease - insights from minimotifs", FRONT BIOSCI., vol. 13, 19 January 2009 (2009-01-19), pages 6455 - 6471 *

Also Published As

Publication number Publication date
WO2011008230A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
EP3778606A3 (en) Condensed imidazolylimidazoles as antiviral compounds
MX341133B (en) Compounds and methods.
PH12012500634A1 (en) Processes for preparing of glucopyranosyl -substituted benzyl -benzene derivatives
EP2452446A4 (en) Midamble for wireless networks
WO2008149345A3 (en) Tri-aryl compounds and compositions comprising the same
WO2010118866A8 (en) Trehalulose-containing composition, its preparation and use
WO2011138040A8 (en) Vaccine against beta-herpesvirus infection and use thereof
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010140765A3 (en) Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
JO3063B1 (en) Innovative compound and methods for its production
WO2010129211A3 (en) Preparation of decitabine
WO2011046303A3 (en) Novel method for preparing entecavir and intermediate used therein
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2011015882A3 (en) Anhydrate of triotropium bromide
WO2011004402A3 (en) Improved process for the preparation of ambrisentan and novel intermediates thereof
WO2011058525A3 (en) Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2012162580A3 (en) Anti-viral compounds
WO2012162578A3 (en) Anti-viral compounds
WO2011018771A3 (en) Process for the preparation of valganciclovir hydrochloride
WO2011067236A3 (en) Raltegravir polymorphs
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2011029536A3 (en) Use of cyclic keto-enols for combating plant pathogenic bacteria
WO2012035303A3 (en) A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
WO2011008230A3 (en) Rapamycin derivatives and ethers of n-propanolamines and uses related to infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10800134

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10800134

Country of ref document: EP

Kind code of ref document: A2